Evidence map›Paper›PMID 35950985›Full record

ArticleThe Permanente journal2022

Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir.

Ingrīda Čēma, Regīna Kleina, Simona Doniņa, Sergejs Isajevs, Tatjana Zablocka, Agnija Rasa, Pēteris Alberts

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Permanente journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ingrīda ČēmaInstitute of Stomatology, Rīga Stradiņš University, Riga, Latvia.
Regīna KleinaMedical faculty, Rīga Stradiņš University, Riga, Latvia.
Simona DoniņaOncology Centre of Latvia, Rīga East University Hospital, Riga, Latvia.
Sergejs IsajevsDepartment of Pathology, Rīga Eastern Clinical University Hospital, Riga, Latvia.
Tatjana ZablockaDepartment of Pathology, Rīga Eastern Clinical University Hospital, Riga, Latvia.
Agnija RasaR&D, Rigvir, Riga, Latvia.
Pēteris AlbertsR&D, Rigvir, Riga, Latvia.
Riga Stradiņš University · LVUniversity of Latvia · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a global problem due to the rising numbers of skin melanoma cases. Current treatment guidelines for patients with stage IIA melanoma recommend only observation after surgery. In this report, the authors describe a patient with stage IIA skin melanoma treated with surgery and Rigvir virotherapy. Two years after the patient discovered a brown spot on the right cheek, surgery was indicated because the mass had started to ulcerate. Rigvir virotherapy was applied both before and after surgery. Observations made more than 7 years after surgery indicated no signs of disease progression. This case report illustrates an early treatment approach. Neoadjuvant treatment for early-stage melanoma is gaining more interest in both scientific and medical communities; therefore, the authors believe it is relevant to share their observations.

Indexed as

MelanomaOncolytic VirusesSkin NeoplasmsCutaneous Malignant MelanomaEnterovirus B, HumanHumanscase reportECHO-7 virusmelanomaoncolytic virusperitumoral administrationRigvirvirotherapy

Identifiers

PMID35950985
PMCPMC9683754
OpenAlexW4290802311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.